Pay in 4 interest-free payments of $5.59 Learn more
Ships within 48 hours · Estimated delivery Aug 9 - Aug 14
Allison Whitten Pfizer's LITFULO meets primary endpoints in Phase 3 vitiligo trials Pfizer reported topline results from two Phase 3 trials of LITFULO (ritlecitinib) in nonsegmental vitiligo, with both the 50 and 100 milligram once-daily doses meeting co-primary endpoints for facial and total body repigmentation over placebo at Week 52
Medicare Reimbursement Cuts and What They Mean The Centers for Medicare & Medicaid Services (CMS) has finalized a new conversion factor of $32.35 for 2025, down from $33.29 in 2024
Clinicians often look at folate levels when considering the psychological wellbeing of patients, especially since these levels can impact the efficacy of antidepressants
Retatrutide is a triple agonist at GLP-1, GIP, and glucagon receptors
The hypothesis for combining them is straightforward yet profound: you get the targeted, potent action of BPC 157 at a specific research site, supported by the systemic, foundational healing environment fostered by TB 500
